Real‐world, open‐label study to evaluate the effectiveness of mirtazapine on sleep quality in outpatients with major depressive disorder. (25th February 2013)

• Record Type: Journal Article
• Authors: Wang, Dan; Li, Zexuan; Li, Lingjiang; Hao, Wei
• Is Part Of: Asia-Pacific psychiatry. Volume 6:Number 2(2014:Jun.)
• Page Start: 152
• Page End: 160
• Publication Date: 2013-02-25
• Subjects: Psychiatry -- Pacific Area -- Periodicals; 616.890095
• DOI: 10.1111/appy.12060
• Languages: English
• ISSNs: 1758-5864

Abstract

<abstract abstract-type="main"> <title>Abstract</title> <sec id="appy12060-sec-0001" sec-type="section"> <title>Introduction</title> <p>The objective of this study was to evaluate the effect of mirtazapine on sleep quality in real‐world outpatients with major depressive disorder (MDD).</p> </sec> <sec id="appy12060-sec-0002" sec-type="section"> <title>Methods</title> <p>Demographic characteristics of MDD outpatients were collected and the Pittsburgh Sleep Quality Index (PSQI) was assessed before and after treatment.</p> </sec> <sec id="appy12060-sec-0003" sec-type="section"> <title>Results</title> <p>In 3, 924 MDD outpatients after treatment, sleep efficiency was significantly higher (<italic>P</italic> < 0.001), global PSQI score was significantly lower (<italic>P</italic> < 0.01), the reduction rates of sleep latency (<italic>P</italic> < 0.01) and global PSQI score (<italic>P</italic> < 0.001) were notably higher, and the proportion of using sleep medications (<italic>P</italic> < 0.05) was significantly lower in the mirtazapine group. In 3, 455 MDD outpatients with insomnia after treatment, the reduction of sleep latency (<italic>P</italic> < 0.001), the prolongation of sleep duration (<italic>P</italic> < 0.001), and the increase in habitual sleep efficiency (<italic>P</italic> < 0.001) were more obvious, the reduction rates of sleep latency (<italic>P</italic> < 0.05) and global PSQI score (<italic>P</italic> < 0.001) were significantly higher, and the proportion of using sleep medications (<italic>P</italic> < 0.001) was significantly lower in the mirtazapine group. In 469 MDD outpatients without insomnia after treatment, the reduction of sleep latency (<italic>P</italic> < 0.05), the increase in sleep duration (<italic>P</italic> < 0.001) and habitual sleep efficiency (<italic>P</italic> < 0.001), and the reduction rate of global PSQI score (<italic>P</italic> < 0.05) were significantly greater in the mirtazapine group.</p> </sec> <sec id="appy12060-sec-0004" sec-type="section"> <title>Discussion</title> <p>This real‐world study suggests that mirtazapine improves sleep quality of MDD outpatients, and decreases the concomitant use of sleep medications.</p> </sec> </abstract>